NCT02761642View on ClinicalTrials.gov

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Anemia
Interventions
DRUG

Epoetin Beta

All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.

Trial Locations (27)

10126

Torino

12100

Cuneo

15033

Casale Monferrato

16132

Genova

20052

Monza

21052

Busto Arsizio

27100

Pavia

31029

Vittorio Veneto

33170

Pordenone

37012

Bussolengo VR

47100

Vecchiazzano

50139

Florence

52100

Arezzo

56100

Pisa

61032

Fano

62100

Macerata

63100

Ascoli Piceno

66100

Chieti

80131

Napoli

84014

Nocera Inferiore

88100

Catanzaro

95100

Catania

98123

Messina

03100

Frosinone

00149

Roma

00168

Roma

07100

Sassari

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02761642 - A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy | Biotech Hunter | Biotech Hunter